Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals, Inc. Announces a Follow-On Offering of Common Stock
Arena Pharmaceuticals, Inc. Announces a Follow-On Offering of Common Stock SAN DIEGO, June 5 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed follow-on offering of
View HTML
Toggle Summary Arena Pharmaceuticals' CEO Jack Lief talks to The Wall Street Transcript
Arena Pharmaceuticals' CEO Jack Lief talks to The Wall Street Transcript NEW YORK--(BUSINESS WIRE)--May 8, 2001--The Wall Street Transcript has published an in-depth interview with Jack Lief, CEO of Arena Pharmaceuticals (Nasdaq:ARNA), in which he talks at length about the company's future.
View HTML
Toggle Summary Arena Pharmaceuticals and Axiom Biotechnologies Sign Binding Letter of Intent for Research Collaboration and Equity Investment by Arena in Axiom
Arena Pharmaceuticals and Axiom Biotechnologies Sign Binding Letter of Intent for Research Collaboration and Equity Investment by Arena in Axiom SAN DIEGO--(BW HealthWire)--April 25, 2001-- The Collaborative Research Program Will Begin Immediately, and Arena's Purchase of $2 Million of Axiom
View HTML
Toggle Summary Arena Pharmaceuticals Announces Second Consecutive Profitable Quarter With Sequential Quarterly Revenue Growth of 32% and Quarterly EPS of $0.05
Arena Pharmaceuticals Announces Second Consecutive Profitable Quarter With Sequential Quarterly Revenue Growth of 32% and Quarterly EPS of $0.05 SAN DIEGO, April 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended March 31, 2001.
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For First Quarter Earnings Conference Call Tuesday April 17, 2001 Live At 4:30 P.M. Eastern Time
Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For First Quarter Earnings Conference Call Tuesday April 17, 2001 Live At 4:30 P.M. Eastern Time SAN DIEGO, April 3 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Receptor Discovery Collaboration With Taisho Pharmaceutical Co., Ltd
Arena Pharmaceuticals, Inc. Announces Receptor Discovery Collaboration With Taisho Pharmaceutical Co., Ltd SAN DIEGO, March 26 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has entered into a receptor-discovery research collaboration with Taisho Pharmaceutical
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Completion of Acquisition Of Bunsen Rush Laboratories, Inc
Arena Pharmaceuticals, Inc. Announces Completion of Acquisition Of Bunsen Rush Laboratories, Inc SAN DIEGO, Feb. 20 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the completion of the acquisition of the outstanding capital stock of Bunsen Rush Laboratories,
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Licensing of 'Obesity' Orphan Receptor Target and Small Molecule Modulators
Arena Pharmaceuticals, Inc. Announces Licensing of 'Obesity' Orphan Receptor Target and Small Molecule Modulators SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of an expansion amendment to its May 29, 2000 research agreement with
View HTML
Toggle Summary Arena Pharmaceuticals Announces Profitable Fourth Quarter With Sequential Quarterly Revenue Growth of 76% and Quarterly EPS of $0.05
Arena Pharmaceuticals Announces Profitable Fourth Quarter With Sequential Quarterly Revenue Growth of 76% and Quarterly EPS of $0.05 SAN DIEGO, Jan. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended December 31, 2000.
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Receipt of Second Milestone Payments From Eli Lilly and Company
Arena Pharmaceuticals, Inc. Announces Receipt of Second Milestone Payments From Eli Lilly and Company SAN DIEGO, Jan. 15 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly
View HTML